Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide plus elranatamab in relapsed or refractory multiple myeloma
2025-522090-11-00Phase 2Authorised
- Sponsor
- Celgene Corporation
- Start
- Jan 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of mezigdomide and elranatamab in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Adverse events and Recommended Phase 2 Dose and schedule. Planned start Jan 2026; status: authorised.
02
Drugs
mezigdomideelranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-522090-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522090-11-00.